Co-Diagnostics, Inc. Common Stock Shares Outstanding

• Co-Diagnostics, Inc. showed an increase of +6,983,336.7% in Common Stock Shares Outstanding from 2025 to 2025.
• This data is from Co-Diagnostics, Inc.'s annual report (Form 10-K), filed with the SEC on March 31, 2026.
• XBRL data for this metric is available from 2016 to 2025 (11 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
• Quarterly values from 10-Q filings: Q2 2017: 9.88 million shares | Q3 2017: 12.28 million shares | Q1 2018: 12.33 million shares | Q2 2018: 12.35 million shares | Q3 2018: 12.67 million shares | Q1 2019: 17.02 million shares | Q2 2019: 17.12 million shares | Q3 2019: 17.34 million shares | Q1 2020: 27.45 million shares | Q2 2020: 27.99 million shares | Q3 2020: 28.16 million shares | Q1 2021: 28.67 million shares | Q2 2021: 28.89 million shares | Q3 2021: 28.89 million shares | Q1 2022: 33.98 million shares | Q2 2022: 33.78 million shares | Q3 2022: 30.92 million shares | Q1 2023: 30.63 million shares | Q2 2023: 30.79 million shares | Q3 2023: 30.66 million shares | Q1 2024: 31.28 million shares | Q2 2024: 31.91 million shares | Q3 2024: 31.93 million shares | Q1 2025: 33.57 million shares | Q2 2025: 36.18 million shares | Q3 2025: 48.14 million shares.
• Over the full 11 years of available data (2016 to 2025), Co-Diagnostics, Inc.'s Common Stock Shares Outstanding has declined by 78.8%.
• Historical annual values: Fiscal year 2025: 2.10 million shares | Fiscal year 2025: 30 shares | Fiscal year 2024: 1.10 million shares | Fiscal year 2023: 31.26 million shares | Fiscal year 2022: 30.87 million shares | Fiscal year 2021: 33.82 million shares | Fiscal year 2020: 28.56 million shares | Fiscal year 2019: 17.34 million shares | Fiscal year 2018: 12.92 million shares | Fiscal year 2017: 12.32 million shares | Fiscal year 2016: 9.88 million shares.
• Data sourced from SEC EDGAR public filings as of August 6, 2026.

Last verified: August 6, 2026